{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:43:43Z","timestamp":1785401023219,"version":"3.56.0"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cluster of Excellence Precision Medicine in Chronic Inflammation","award":["EXC 2167"],"award-info":[{"award-number":["EXC 2167"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["LU 877\/25-1"],"award-info":[{"award-number":["LU 877\/25-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"award":["LU 877\/25-1"],"award-info":[{"award-number":["LU 877\/25-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Schleswig-Holstein Excellence Chair Program of the State of Schleswig-Holstein"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chronic inflammatory barrier diseases (CIBDs) affect many women of reproductive age, yet the safety of biologics during pregnancy remains inadequately investigated. This retrospective cohort study used the US Collaborative Network of TriNetX to evaluate the risk of adverse pregnancy outcomes (APOs) among women with CIBD receiving tumor necrosis factor inhibitors (TNFis), interleukin-23 inhibitors (IL-23is), or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), compared with untreated CIBD controls and the general pregnant population. Among 1842 pregnant women with CIBD receiving systemic therapy, 1188 were exposed to TNFis, 170 to IL-23is, 370 to azathioprine (csDMARD), and 114 to methotrexate (MTX) (csDMARD). The incidence of any APO ranged from 11% in untreated CIBD controls to 19% with ustekinumab (IL-12\/23i). Among treatment groups, rates were 17% with TNFis, 18% with IL-23is, 13% with azathioprine, and 15% with MTX, compared with 17% in the general pregnant population. APO rates were comparable between the overall TNFi group and the TNFi group excluding certolizumab pegol (CZP) (TNFi). In the only non-exploratory comparison, TNFi exposure was associated with higher risks of (pre-)eclampsia and hypertension but a lower risk of abortion or intrauterine death versus CIBD controls, with no significant difference for overall APO. No treatment group showed a markedly increased overall APO risk, supporting tailored decision-making that balances the consequences of uncontrolled maternal disease against individual treatment-associated risks.<\/jats:p>","DOI":"10.3390\/biom16081083","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:36:13Z","timestamp":1784878573000},"page":"1083","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6312-0651","authenticated-orcid":false,"given":"Inga Catharina","family":"Brouer","sequence":"first","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Zani","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-8491","authenticated-orcid":false,"given":"Philip","family":"Curman","sequence":"additional","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck, 23562 L\u00fcbeck, Germany"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden"},{"name":"Dermatology and Venereology Division, Department of Medicine (Solna), Karolinska Institutet, 17177 Stockholm, Sweden"},{"name":"Dermato-Venereology Clinic, Karolinska University Hospital, 17176 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck, 23562 L\u00fcbeck, Germany"},{"name":"Department of Dermatology, University Medical Centre of the State of Schleswig-Holstein (UKSH), 23538 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, 23562 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2020.1719833","article-title":"Epidemiology of major chronic inflammatory immune-related skin diseases in 2019","volume":"16","author":"Pezzolo","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ujiie, H., Rosmarin, D., Sch\u00f6n, M.P., St\u00e4nder, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., and Cole, C. (2022). Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Front. Med., 9.","DOI":"10.3389\/fmed.2022.875492"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdin.2024.11.003","article-title":"Global trends in immune mediated inflammatory diseases: Psoriasis, atopic dermatitis, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis","volume":"18","author":"Chiang","year":"2025","journal-title":"JAAD Int."},{"key":"ref_4","unstructured":"National Psoriasis Foundation (2025, August 06). Psoriasis Statistics. Available online: https:\/\/www.psoriasis.org\/psoriasis-statistics\/."},{"key":"ref_5","unstructured":"GBD 2021 Rheumatoid Arthritis Collaborators (2023). Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol., 5, e594\u2013e610."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_7","first-page":"145","article-title":"Pregnancy and autoimmune disease","volume":"119","author":"Merz","year":"2022","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2510504","DOI":"10.1001\/jamanetworkopen.2025.10504","article-title":"Use of biologics during pregnancy among patients with autoimmune conditions","volume":"8","author":"Ewig","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.14309\/ajg.0000000000002553","article-title":"Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: Results from the PIANO registry","volume":"119","author":"Chugh","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","first-page":"e191","article-title":"Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn\u2019s disease and paradoxical psoriasis","volume":"30","author":"Mook","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","first-page":"1240","article-title":"Treatment of severe psoriasis with ustekinumab during pregnancy","volume":"11","author":"Andrulonis","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102193","DOI":"10.1016\/j.eclinm.2023.102193","article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: Findings from the global burden of disease study 2019","volume":"64","author":"Wu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/1471-0528.17885","article-title":"Changes in the prevalence of maternal chronic conditions during pregnancy: A nationwide age\u2013period\u2013cohort analysis","volume":"132","author":"Lundborg","year":"2025","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/1471-0528.17093","article-title":"Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: A systematic review and meta-analysis","volume":"129","author":"Alqatari","year":"2022","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","article-title":"Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: A systematic review and meta-analysis of observational studies","volume":"59","author":"Tsao","year":"2020","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/acr.24813","article-title":"Ustekinumab safety in pregnancy: A comprehensive review","volume":"75","author":"Gorodensky","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ludwig, R.J., Anson, M., Zirpel, H., Thaci, D., Olbrich, H., Bieber, K., Kridin, K., Dempfle, A., Curman, P., and Zhao, S.S. (2025). A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1516126"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Deng, Z., Wang, S., Wu, C., and Wang, C. (2023). IL-17 inhibitor-associated inflammatory bowel disease. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1124628"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Skorpen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","unstructured":"Gerriets, V., Goyal, A., and Khaddour, K. (2025, June 06). Tumor Necrosis Factor Inhibitors, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482425\/."},{"key":"ref_22","unstructured":"Horsham. Johnson & Johnson (2025, June 06). TREMFYA\u00ae (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson\u2019s Leadership in Inflammatory Bowel Disease. Available online: https:\/\/www.jnj.com\/media-center\/press-releases\/tremfya-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-johnson-johnsons-leadership-in-inflammatory-bowel-disease."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (2019). ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation. Obstet. Gynecol., 133, e287\u2013e295.","DOI":"10.1097\/AOG.0000000000003176"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0960327114550882","article-title":"Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: A systematic review with meta-analysis","volume":"34","author":"Mozaffari","year":"2015","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_26","first-page":"716","article-title":"Current aspects of antirheumatic therapy in pregnancy planning, during pregnancy and breastfeeding","volume":"80","year":"2021","journal-title":"Z. Rheumatol."},{"key":"ref_27","unstructured":"National Institutes of Health (2026, April 28). Methotrexate Injection, USP, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=b585f621-f6c9-4735-ab61-bd1b401f3df0."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.38368","article-title":"Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: A prospective multicenter cohort study","volume":"66","author":"Chambers","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102676","DOI":"10.1016\/j.jaut.2021.102676","article-title":"Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-\u03b1 during pregnancy: A systemic review and meta-analysis","volume":"122","author":"Barenbrug","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ghazawi, F.M., Mahmood, F., Kircik, L., Poulin, Y., Bourcier, M., Vender, R., Wiseman, M.C., Lynde, C., and Litvinov, I.V. (2021). A review of the efficacy and safety for biologic agents targeting IL-23 in treating psoriasis with the focus on tildrakizumab. Front. Med., 8.","DOI":"10.3389\/fmed.2021.702776"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000542217","article-title":"Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: Findings from WHO pharmacovigilance study","volume":"186","author":"Jeong","year":"2024","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_35","first-page":"123","article-title":"Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis","volume":"6","author":"Koutruba","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1523-1747.2003.12012.x","article-title":"IL-12 Completely Blocks Ultraviolet-Induced Secretion of Tumor Necrosis Factor \u03b1 from Cultured Skin Fibroblasts and Keratinocytes","volume":"120","author":"Werth","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-016-8596-x","article-title":"Tumor necrosis factor-alpha and pregnancy: Focus on biologics. An updated and comprehensive review","volume":"53","author":"Llurba","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acr.24037","article-title":"Mediation of adverse pregnancy outcomes in autoimmune conditions by pregnancy complications: A mediation analysis of autoimmune conditions and adverse pregnancy outcomes","volume":"72","author":"Bandoli","year":"2020","journal-title":"Arthritis Care Res."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1083\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:18:00Z","timestamp":1785039480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biom16081083"],"URL":"https:\/\/doi.org\/10.3390\/biom16081083","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}